Effect of Maolactin on recovery and muscle comfort after exercise
Effect of Maolactin™ FMR Supplementation on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population: a Double-blind Randomized Placebo-controlled Study
This study is testing if a supplement called Maolactin can help healthy adults feel less sore and recover better after exercising.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | RDC Clinical Pty Ltd Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Brisbane, Queensland) |
| Trial ID | NCT06436781 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the impact of Maolactin FMR supplementation on post-exercise inflammation, recovery, muscle fatigue, and pain in healthy adults aged 18-65. It is a double-blind, randomized, placebo-controlled study conducted over 10 weeks, with 8 weeks of supplementation. Participants will be monitored for changes in muscle comfort and recovery metrics following exercise. The study aims to determine if Maolactin can enhance recovery in a generally active population.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 18-65 with a BMI between 19.0 and 29.9 who engage in low to moderate exercise.
Not a fit: Patients with serious or unstable illnesses, high-intensity training regimens, or current malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new supplement option to improve exercise recovery and reduce muscle discomfort for active individuals.
How similar studies have performed: Other studies have shown promise with similar supplementation approaches, but the specific effects of Maolactin remain to be fully explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults 18-65 years old * Generally healthy * BMI 19.0 - 29.9 kg/m2 * Able to provide informed consent * Generally active, low to moderately trained (with a minimum of 1 resistance exercise sessions per week) * Agree not to change current diet and/or exercise frequency or intensity during study period * Agree to not participate in another clinical trial while enrolled in this trial Exclusion Criteria: * Undertaking high intensity exercise training and or undertaking more than 3 days of resistance training per week. * Serious illness(1) e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions * Unstable illness(2) e.g., diabetes and thyroid gland dysfunction * Unstable intake of any medication or supplement(3) * Acute injuries on reporting area * Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin * Receiving medications known to affect inflammation such as steroids * Active smokers, nicotine use or drug (prescription or illegal substances) abuse * Chronic past and/or current alcohol use (\>21 alcoholic drinks per week) * Pregnant or lactating women * Allergic to any of the ingredients in active or placebo formula * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion 1. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments. 2. An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. 3. An unstable intake is any dose that has changed by more than 10% of the previous dose in the past 4-weeks
Where this trial is running
Brisbane, Queensland
- RDC Clinical Pty Ltd — Brisbane, Queensland, Australia (Recruiting)
Study contacts
- Principal investigator: David Briskey, PhD — RDC Clinical Pty Ltd
- Study coordinator: Amanda Rao, PhD
- Email: amanda@rdcglobal.com.au
- Phone: +61 414 488 559
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.